Factory Mutual Insurance Co. held its stake in Mylan (NASDAQ:MYL) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 46,000 shares of the company’s stock at the end of the first quarter. Factory Mutual Insurance Co.’s holdings in Mylan were worth $1,794,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in MYL. State Street Corp raised its position in Mylan by 7.8% in the fourth quarter. State Street Corp now owns 19,942,043 shares of the company’s stock valued at $760,788,000 after buying an additional 1,446,244 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its position in Mylan by 31.2% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 5,970,200 shares of the company’s stock valued at $227,763,000 after buying an additional 1,420,000 shares in the last quarter. Northern Trust Corp raised its position in Mylan by 2.2% in the third quarter. Northern Trust Corp now owns 5,304,333 shares of the company’s stock valued at $202,201,000 after buying an additional 114,280 shares in the last quarter. Norges Bank purchased a new position in Mylan during the fourth quarter valued at approximately $166,189,000. Finally, Camber Capital Management LLC raised its position in Mylan by 7.0% in the fourth quarter. Camber Capital Management LLC now owns 4,145,889 shares of the company’s stock valued at $158,166,000 after buying an additional 272,889 shares in the last quarter. Hedge funds and other institutional investors own 60.89% of the company’s stock.
Mylan (NASDAQ:MYL) traded down 0.67% during mid-day trading on Friday, reaching $36.83. 3,876,749 shares of the company’s stock were exchanged. Mylan has a 52 week low of $33.60 and a 52 week high of $50.40. The stock has a market cap of $19.72 billion, a P/E ratio of 40.03 and a beta of 1.14. The stock has a 50-day moving average price of $40.82 and a 200-day moving average price of $38.68.
Mylan (NASDAQ:MYL) last released its earnings results on Wednesday, March 1st. The company reported $1.57 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.42 by $0.15. The firm had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.18 billion. Mylan had a return on equity of 22.04% and a net margin of 2.50%. During the same quarter in the previous year, the business posted $1.22 EPS. On average, analysts forecast that Mylan will post $5.29 earnings per share for the current year.
Several equities analysts have recently commented on MYL shares. BTIG Research restated a “buy” rating and set a $55.00 price target on shares of Mylan in a research report on Tuesday, January 3rd. Vetr lowered shares of Mylan from a “strong-buy” rating to a “buy” rating and set a $42.20 price target for the company. in a research report on Monday, January 2nd. Mizuho restated a “buy” rating and set a $47.00 price target on shares of Mylan in a research report on Tuesday, February 28th. Deutsche Bank AG lowered their price target on shares of Mylan from $52.00 to $51.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Barclays PLC restated an “equal weight” rating and set a $47.00 price target (up previously from $44.00) on shares of Mylan in a research report on Saturday, March 11th. One analyst has rated the stock with a sell rating, nine have given a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $51.96.
In other Mylan news, major shareholder Laboratories Abbott sold 44,000,000 shares of the business’s stock in a transaction that occurred on Thursday, March 23rd. The stock was sold at an average price of $41.60, for a total value of $1,830,400,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.71% of the company’s stock.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.